Marijuana Studies and

Cannabis Research

09/28/2018
Author(s): Katarzyna Starowicz,∗ Natalia Malek and Barbara Przewlocka. Cannabidiol has been shown to be effective in treating pain that is resistant to conventional treatment, as suggested by a growing number of laboratory studies. View study
09/28/2018
Author(s): Sven Gottschling, Homburg/Saar. Therapists are always facing enormous problems when it comes to treating children with life-limiting illnesses and chronic pain, since most medications are not available in usable pediatric versions, not to mention the adverse effects they cause. It is in these cases where cannabinoids have an interesting therapeutic potential. View study
09/28/2018
Author(s): Marcos Hortes N Chagas, Antonio W Zuardi, Vitor Tumas, Márcio Alexandre Pena-Pereira, Emmanuelle T Sobreira, Mateus M Bergamaschi, Antonio Carlos dos Santos, Antonio Lucio Teixeira, Jaime EC Hallak and José Alexandre S Crippa. CBD has a promising use to improve the quality of life of patients with Parkinson’s disease without psychiatric comorbidities. View study
09/28/2018
Author(s): Sandeep Vasant More and Dong-Kug Choi*. The use of cannabinoids as a new therapeutic target has been recommended as a promising therapy for Parkinson’s disease, as the growing evidence suggests a prominent modulating function of the cannabinoid signaling system in the basal ganglia. View study
09/28/2018
Author(s): Katerˇina Venderova´, PharmD, PhD, Evzˇen Ru˚zˇicˇka, MD, DSc, Viktor Vorˇı´sˇek, PharmD, and Peter Visˇnˇovsky´, MD, PhD. Interesting questionnaires that show that bradykinesia seems to be the symptom most commonly improved by cannabinoids, followed by muscle rigidity and tremor. In addition, the use of cannabis causes the relief of dyskinesias induced by dopaminergics. View study
09/28/2018
Author(s): Marta Celorrio a, b, Estefanía Rojo-Bustamante a, b, Diana Fernandez-Su  arez  a, Elena Saez  c, Ander Estella-Hermoso de Mendoza c, Christa E. Müller d, María J. Ramírez e, g, Julen Oyarzabal  c, Rafael Franco a, f, María S. Aymerich. For the first time it is demonstrated that the activation of the GPR55 receptor by. View study
09/28/2018
Author(s): M. H. N. Chagas MD PhD, A. L. Eckeli MD PhD, A. W. Zuardi MD PhD, M. A. Pena-Pereira MD, M. A. Sobreira-Neto MD, E. T. Sobreira PhD, M. R. Camilo MD, M. M. Bergamaschi PhD, C. H. Schenck MD, J. E. C. Hallak MD PhD, V. Tumas MD PhD and J. A. S. Crippa MD PhD. A synthetic cannabidiol isomer (CBD) may be beneficial in combating Parkinson’s disease. View study
09/28/2018
Author(s): Lu Song Xinxin Yang Yaping Ma Na Wu Zhenguo Liu. The dopamine precursor L-3,4-dihydroxyphenylalanine (L-DOPA) has been used effectively to treat Parkinson’s disease. However, its long-term administration produces serious complications. In this study, the active participation of CB1 receptors in the regulation of the action of L-DOPA during the treatment of Parkinson’s Disease is evidenced. View study
09/28/2018
Author(s): S G Fagan and V A Campbell. Modulation of the cannabinoid system has shown beneficial effects and constitutes a possibility for the treatment of neurodegenerative disorders such as Parkinson’s disease. View study
09/28/2018
Author(s): Devan Kansagara, MD, MCR, Maya O’Neil, Shannon Nugent, Michele Freeman, Allison Low, Karli Kondo, Camille Elven, Bernadette Zakher, Makalapua Motu’apuaka, Robin Paynter, and Benjamin J Morasco. Recent studies indicate that between 45% and 80% of people who seek cannabis for medical purposes do so to control pain, which suggests its therapeutic potential in patients with chronic pain. View study
09/28/2018
Author(s): Jahan P. Marcu, Rigel T. Christian, Darryl Lau, Anne J. Zielinski, Maxx P. Horowitz, Jasmine Lee, Arash Pakdel, Juanita Allison, Chandani Limbad, Dan H. Moore, Garret L. Yount, Pierre-Yves Desprez, and Sean D. McAllister. Adding cannabidiol to Δ9-THC may improve the effectiveness of Δ9-THC in the treatment of glioblastoma in patients with cancer. When treating the cells with both compounds it was observed that these acted synergistically to inhibit cell proliferation. View study
09/28/2018
Author(s): Francieli Vuolo, Fabricia Petronilho, Beatriz Sonai, Cristiane Ritter, Jaime E. C. Hallak, Antonio Waldo Zuardi, José A. Crippa, and Felipe Dal-Pizzol. There is a great possibility that CBD can be used as a pharmacological treatment for asthma, because it can modulate the inflammatory responses of the disease. View study
09/28/2018
Author(s): Elspeth E.Pickering, Stephen J. Semple, Muhummad S. Nazir, Kevin Murphy, Thomas M. Snow, Andrew R. Cummin, Shakeeb H. Moosavi, Abraham Guz, and Anita Holdcroft. To test the hypothesis that unpleasant respiratory problems will improve in humans with cannabinoids without respiratory depression, a double-blind, randomized, placebo-controlled study with two days of testing in five subjects with normal chronic obstructive pulmonary disease ( COPD) and four other subjects. After administering the drug, subjects with COPD experienced dyspnea (shortness of breath) less frequently than placebo. However, a more specific stimulus for “air hunger” may be necessary in order to directly demonstrate an effect of cannabidiol on dyspnea. View study
09/28/2018
Author(s): Luciano Rezende Vilela, Lindisley Ferreira Gomides, Bruna Araújo David, Maísa Mota Antunes, Ariane Barros Diniz, Fabrício de Araújo Moreira, and Gustavo Batista Menezes. The cannabinoid system may have an important role in the treatment of cocaine abuse, since its activation produces protective actions in the brain and liver, minimizing inflammatory lesions. View study
09/28/2018
Author(s): Elspeth E.Pickering, Stephen J. Semple, Muhummad S. Nazir, Kevin Murphy, Thomas M. Snow, Andrew R. Cummin, Shakeeb H. Moosavi, Abraham Guz, and Anita Holdcroft. To test the hypothesis that unpleasant respiratory problems will improve in humans with cannabinoids without respiratory depression, a double-blind, randomized, placebo-controlled study with two days of testing in five subjects with normal chronic obstructive pulmonary disease ( COPD) and four other subjects. After administering the drug, subjects with COPD experienced dyspnea (shortness of breath) less frequently than placebo. However, a more specific stimulus for “air hunger” may be necessary in order to directly demonstrate an effect of cannabidiol on dyspnea. View study
09/28/2018
Author(s): Giovanni Marsicano, Sharon Goodenough, Krisztina Monory, Heike Hermann, Matthias Eder, Astrid Cannich, Shahnaz C. Azad, Maria Grazia Cascio, Silvia Ortega Gutie´rrez, Mario van der Stelt, Maria Luz Lo´pez-Rodrı´guez, Emilio Casanova, Gu¨nther Schu¨tz, Walter Zieglga¨nsberger, Vincenzo Di Marzo, Christian Behl, Beat Lutz. The endogenous cannabinoid system provides on-demand protection against acute excitotoxicity in neurons of the central nervous system. View study
09/28/2018
Author(s): Carol Hamelink, Aidan Hampson, David A. Wink, Lee E. Eiden, and Robert L. Eskay. Cannabidiol (CBD) was evaluated as a neuroprotector in a borage model of ethanol. When administered at the same time as excessive exposure to ethanol, CBD protects against hippocampal and entorhinal cortical neurodegeneration in a dose-dependent manner. This study provides the first demonstration of CBD as a neuroprotective in vivo and shows the efficacy of lipophilic antioxidants in the prevention of brain lesions induced by excess ethanol. View study
09/28/2018
Author(s): Hjorthoj CR, Baker A, Fohlmann A, Nordentoft M. Studies on the effectiveness of psychosocial interventions in patients with schizophrenia and cannabis use disorders.View study
09/28/2018
Author(s): Benjamin C McLoughlin, Jonathan A Pushpa-Rajah, Donna Gillies, John Rathbone, Hannele Variend, Eliana Kalakouti, Katerina Kyprianou. Cannabidiol may have an antipsychotic effect in patients with schizophrenia.View study
09/28/2018
Author(s): Leonora E Long, Daniel T Malone and David A Taylor. Cannabidiol acts as an agonist of the vanilloid channel 1 in the transient receptor potential family (TRPV1) and also to inhibit the hydrolysis and cellular uptake of the endogenous cannabinoid anandamide. Cannabidiol also has potential as an antipsychotic. View study
09/28/2018
Author(s): LS Whyte, L Ford, SA Ridge, GA Cameron, MJ Rogers and RA Ross. In this study, the effects of cannabinoids on human bone cells in vitro were investigated, and it was shown that molecules that modulate the endocannabinoid system could be therapeutic in bone diseases. View study
09/28/2018
Author(s): Yong-Xin Sun, Ai-Hua Xu, Yang Yang, Jia-Xing Zhang, and Ai-Wen Yu. It has been discovered that cannabinoid receptors contribute to the renewal of bone mass, thus being able to play an important role in the treatment of osteoporosis. View study
09/28/2018
Author(s): I Bab1 and A Zimmer. Recent studies in mice suggest that cannabinoid receptors could be an important objective to consider for the development of cannabinoid drugs to combat osteoporosis and to develop diagnostic measures to identify polymorphisms sensitive to osteoporosis in the CNR2 gene. View study
09/28/2018
Author(s): L. Lorente Fernández b, E. Monte Boquet b, F. Pérez-Miralles a, I. Gil Gómez b, M. Escutia Roig a, I. Boscá Blascoa, J.L. Poveda Andrés b, B. Casanova-Estruch. THC and CBD seem to be an excellent alternative for multiple sclerosis treatments, since it improves refractory spasticity and has an acceptable toxicity profile. View study